Germany
· Delayed Price · Currency is EUR Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of EUR 12.06 billion. The enterprise value is 20.55 billion.
| Market Cap | 12.06B |
| Enterprise Value | 20.55B |
Important Dates
The last earnings date was Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | May 16, 2025 |
Share Statistics
| Current Share Class | 421.37M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.86% |
| Shares Change (QoQ) | -1.85% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 368.40M |
Valuation Ratios
The trailing PE ratio is 11.93 and the forward PE ratio is 5.23.
| PE Ratio | 11.93 |
| Forward PE | 5.23 |
| PS Ratio | 5.76 |
| PB Ratio | 1.33 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 4.83 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 20.33 |
| EV / Sales | 10.29 |
| EV / EBITDA | n/a |
| EV / EBIT | 11.94 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.78.
| Current Ratio | 1.56 |
| Quick Ratio | 1.56 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 7.71 |
Financial Efficiency
Return on equity (ROE) is 18.00% and return on invested capital (ROIC) is 7.11%.
| Return on Equity (ROE) | 18.00% |
| Return on Assets (ROA) | 7.04% |
| Return on Invested Capital (ROIC) | 7.11% |
| Return on Capital Employed (ROCE) | 11.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +18.40% |
| 50-Day Moving Average | 29.11 |
| 200-Day Moving Average | 27.20 |
| Relative Strength Index (RSI) | 46.51 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.90 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of EUR 2.09 billion and earned 1.01 billion in profits. Earnings per share was 2.27.
| Revenue | 2.09B |
| Gross Profit | 2.07B |
| Operating Income | 1.76B |
| Pretax Income | 1.64B |
| Net Income | 1.01B |
| EBITDA | n/a |
| EBIT | 1.76B |
| Earnings Per Share (EPS) | 2.27 |
Balance Sheet
The company has 1.02 billion in cash and 7.05 billion in debt, giving a net cash position of -6.03 billion.
| Cash & Cash Equivalents | 1.02B |
| Total Debt | 7.05B |
| Net Cash | -6.03B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.06B |
| Book Value Per Share | 14.54 |
| Working Capital | 610.99M |
Cash Flow
| Operating Cash Flow | 2.50B |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 99.04%, with operating and profit margins of 83.95% and 48.26%.
| Gross Margin | 99.04% |
| Operating Margin | 83.95% |
| Pretax Margin | 78.12% |
| Profit Margin | 48.26% |
| EBITDA Margin | n/a |
| EBIT Margin | 83.95% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 2.66%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 2.66% |
| Dividend Growth (YoY) | 5.31% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 34.60% |
| Buyback Yield | 1.86% |
| Shareholder Yield | 4.53% |
| Earnings Yield | 8.38% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.7 |
| Piotroski F-Score | n/a |